H. Wilke

561 total citations
16 papers, 423 citations indexed

About

H. Wilke is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, H. Wilke has authored 16 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Surgery. Recurrent topics in H. Wilke's work include Gastric Cancer Management and Outcomes (9 papers), Metastasis and carcinoma case studies (6 papers) and Lung Cancer Treatments and Mutations (5 papers). H. Wilke is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Metastasis and carcinoma case studies (6 papers) and Lung Cancer Treatments and Mutations (5 papers). H. Wilke collaborates with scholars based in Germany and France. H. Wilke's co-authors include U. Fink, W. Achterrath, P. Preusser, Jochen Meyer, Luigi Lenaz, H J Meyer, A. Heinicke, Christoph Schuhmacher, H. J. Stein and M. Stahl and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and European Journal of Cancer.

In The Last Decade

H. Wilke

15 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Wilke Germany 7 285 211 178 73 71 16 423
Harika Tirumani United States 10 208 0.7× 59 0.3× 88 0.5× 42 0.6× 81 1.1× 22 303
Syoichi Fujii Japan 8 280 1.0× 203 1.0× 195 1.1× 102 1.4× 8 0.1× 12 446
J. T. Plukker Netherlands 6 213 0.7× 73 0.3× 174 1.0× 20 0.3× 19 0.3× 13 352
G.F. Samelis Greece 10 159 0.6× 247 1.2× 121 0.7× 16 0.2× 68 1.0× 23 372
Abdul Hamid El Chafic United States 9 198 0.7× 212 1.0× 305 1.7× 59 0.8× 18 0.3× 25 406
Maica Galán Spain 12 208 0.7× 190 0.9× 137 0.8× 58 0.8× 20 0.3× 29 395
H J Meyer Germany 7 447 1.6× 173 0.8× 288 1.6× 181 2.5× 10 0.1× 14 575
Alvise Frasson Italy 5 216 0.8× 123 0.6× 58 0.3× 33 0.5× 59 0.8× 7 268
Keisei Taku Japan 12 349 1.2× 195 0.9× 223 1.3× 107 1.5× 8 0.1× 33 459
Orhan Bulut Denmark 14 111 0.4× 337 1.6× 371 2.1× 67 0.9× 24 0.3× 57 486

Countries citing papers authored by H. Wilke

Since Specialization
Citations

This map shows the geographic impact of H. Wilke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Wilke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Wilke more than expected).

Fields of papers citing papers by H. Wilke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Wilke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Wilke. The network helps show where H. Wilke may publish in the future.

Co-authorship network of co-authors of H. Wilke

This figure shows the co-authorship network connecting the top 25 collaborators of H. Wilke. A scholar is included among the top collaborators of H. Wilke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Wilke. H. Wilke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Vermorken, Jan B., H. Wilke, Jean Bourhis, et al.. (2010). First-line treatment patterns for recurrent and/or metastatic head and neck cancer (R/M HNC) in Europe.. Journal of Clinical Oncology. 28(15_suppl). e16016–e16016. 3 indexed citations
2.
Vanhoefer, U., Thomas Wagner, Manfred P. Lutz, et al.. (2001). Randomized phase II study of weekly 24 h infusion of high dose 5-FU ± folinic acid (HD-FU±FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. European Journal of Cancer. 37. S27–S27. 16 indexed citations
3.
Stahl, M., U. Vanhoefer, U. Fink, et al.. (1996). Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma. Oncology Research and Treatment. 19(5). 416–418. 6 indexed citations
4.
5.
Fink, U., H. J. Stein, Christoph Schuhmacher, & H. Wilke. (1995). Neoadjuvant chemotherapy for gastric cancer: Update. World Journal of Surgery. 19(4). 509–516. 37 indexed citations
6.
Wilke, H., A. Harstrick, & S. Seeber. (1995). The Role of Folinic Acid in Combination with 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer. Oncology Research and Treatment. 18(1). 65–67. 1 indexed citations
7.
Wilke, H., P. Preusser, M. Stahl, et al.. (1994). Phase II Study with Folinic Acid, Etoposide, 5-Fluorouracil and Cisplatin (FLEP) for Advanced Gastric Cancer. Oncology Research and Treatment. 17(2). 154–157.
8.
Stamatis, Georgios, H. Wilke, Wilfried Eberhardt, et al.. (1994). [Surgery of locally advanced non-small-cell bronchial cancer after intensive preoperative chemo-/radiotherapy].. PubMed. 65(1). 42–7. 2 indexed citations
9.
Harstrick, A., Carsten Bokemeyer, Andreas Mügge, et al.. (1993). Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 72(7). 2242–2247. 89 indexed citations
10.
Schmoll, Hans‐Joachim, Carsten Bokemeyer, A. Harstrick, et al.. (1992). Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors.. PubMed. 39(9). 961–961. 1 indexed citations
11.
Stahl, M., H. Wilke, P. Preusser, et al.. (1991). Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk. Oncology Research and Treatment. 14(4). 314–318. 5 indexed citations
12.
Preusser, P., H. Wilke, W. Achterrath, et al.. (1989). Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.. Journal of Clinical Oncology. 7(9). 1310–1317. 238 indexed citations
13.
Preusser, P., H. Wilke, W. Achterrath, et al.. (1988). Phase-II-Study with EAP (Etoposide, Adriamycin, Cis- Platinum) in Patients with Primary Inoperable Gastric Cancer and Advanced Disease. Recent results in cancer research. 110. 198–206. 5 indexed citations
14.
Preusser, P., H. Wilke, W. Achterrath, et al.. (1987). Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin.. PubMed. 6(5). 1195–6. 10 indexed citations
15.
Harms, D., et al.. (1980). Zentrales Tumorregister bei der Gesellschaft für Pädiatrische Onkologie e.V. - erster Arbeitsbericht1,2. Klinische Pädiatrie. 192(2). 99–108. 1 indexed citations
16.
Wilke, H. & D. Harms. (1979). Alpha-1-Fetoprotein im Tumorgewebe. DMW - Deutsche Medizinische Wochenschrift. 104(43). 1527–1529. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harika Tirumani Breakdown of academic impact, for papers by Syoichi Fujii Breakdown of academic impact, for papers by J. T. Plukker Breakdown of academic impact, for papers by G.F. Samelis Breakdown of academic impact, for papers by Abdul Hamid El Chafic Breakdown of academic impact, for papers by Maica Galán Breakdown of academic impact, for papers by H J Meyer Breakdown of academic impact, for papers by Alvise Frasson Breakdown of academic impact, for papers by Keisei Taku Breakdown of academic impact, for papers by Orhan Bulut
Rankless by CCL
2026